Tissue Engineered - Skin Substitutes Market By Type 2022 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Tissue Engineered - Skin Substitutes Market
Tissue Engineered - Skin Substitutes Market: By Type (Acellular, Cellular Allogeneic, Cellular Autologous, Others); By Application (Burn Injury, Diabetic/Vascular Ulcer and Others); & By Region - (2016-2022)
Report Code : HCR 0408
Updated Date: 14 September, 2017  

Copies sold

    Client Rating

  • Report Description
  • Table of Contents
  • Customization Options
1. Tissue Engineered – Skin Substitute Market Overview
2. Tissue Engineered – Skin Substitute Market Executive Summary
3. Tissue Engineered – Skin Substitute Market Landscape
   3.1. Market Share Analysis
   3.2. Financial Analysis of Top 5 Players
   3.3. Product Benchmarking
   3.4. End-User Profiling
   3.5. Patent Analysis
4. Tissue Engineered – Skin Substitute Market Forces
   4.1. Market Drivers
      4.1.1. Burgeoning Population and a Rapidly Growing Healthcare Infrastructure in Emerging Economies
      4.1.2. Increasing Incidence Rate of Skin Disorders
      4.1.3. Rising Healthcare Expenditure and Aging Population
      4.1.4. Growing Incidences of Vascular Diseases and Injuries
   4.2. Market Constraints & Challenges
      4.2.1. Presence of Bitter Aftertaste When Consumed
      4.2.2. Possible Side Effects on the Reproductive, Renal and Cardio-Vascular Systems
      4.2.3. Cannot be Used as a Sugar Substitute in Certain Types of Food 
   4.3. Market Challenges
      4.3.1. High Cost Compared to Volume Produced
      4.3.2. High Level of Adulteration Among Stevia Products
   4.4. Attractiveness of the Stevia Industry
      4.4.1. Power of Suppliers
      4.4.2. Power of Customers
      4.4.3. Threat of New entrants
      4.4.4. Threat of Substitution
      4.4.5. Degree of Competition
5. Tissue Engineered – Skin Substitute Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Opportunity Analysis
      5.2.1. Growing opportunities of skin substitute technologies
      5.2.2. Increasing economic  variance in emerging countries
      5.2.3. Growing need of tissue engineering in medical field  
      5.2.4. Increasing priority  for improvement of health in developing countries
      5.2.5. Growing incidences of vascular diseases and injuries
   5.3. Market Life Cycle Analysis
6. Tissue Engineered – Skin Substitute Market – By Type 
   6.1. Introduction
   6.2. Acellular
   6.3. Cellular Allogeneic
   6.4. Cellular Autologous
   6.5. Others
7. Tissue Engineered – Skin Substitute Market – By Application
   7.1. Introduction
   7.2. Burn Injury
   7.3. Diabetic/Vascular Ulcer
   7.4. Others 
8. Tissue Engineered – Skin Substitute Market – By Geography
   8.1. Introduction
   8.2. North America
      8.2.1. U.S.
      8.2.2. Canada
      8.2.3. Mexico
   8.3. Europe
      8.3.1. U.K.
      8.3.2. Germany
      8.3.3. France
      8.3.4. Italy
      8.3.5. Spain
      8.3.6. Russia
      8.3.7. Rest of Europe
   8.4. Asia-Pacific
      8.4.1. China
      8.4.2. Japan
      8.4.3. Australia & New Zealand
      8.4.4. India
      8.4.5. Rest of APAC
   8.5. RoW
      8.5.1. Middle East 
      8.5.2. Africa
      8.5.3. South America
9. Tissue Engineered – Skin Substitute Market Entropy
10. Company Profiles
   10.1. 3M Inc (U.S.)
   10.2. Acelity L.P. Inc (U.S.)
   10.3. BSN Medical GmbH (Germany)
   10.4. Convatec Group Plc (U.K.)
   10.5. Integra LifeSciences Holdings Corporation (U.S.)
   10.6. Molnlycke Healthcare AB (Sweden)
   10.7. Organogenesis Inc. (U.S.)
   10.8. Shire Plc (U.S.)
   10.9. Smith & Nephew PLC (U.K.)
   10.10. Medtronic (Ireland)
*More than 10 Companies are profiled in this Research Report*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix
   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Tissue engineering is referred to the practice of combining scaffolds, cells, and biologically active molecules into functional tissues. Its goal is to assemble functional constructs that restore, maintain, or improve damaged tissues or whole organs. Skin substitute are engineered tissues that have been approved by the FDA. The tissue engineered skin substitutes market is estimated to witness significant growth during the forecast period owing to increase in diabetic and vascular ulcer patients, rising geriatric population and growing demand for minimally invasive surgical products. 

The global tissue engineered skin substitute market has been analyzed with respect to different parameters such as demand, supply, end-use applications and companies involved. The tissue engineered skin substitute market has been categorized based on types and end-use applications. On the basis of type the market is segmented into acellulaar, cellular allogenic, cellular autologous and others, by applications it is segmented into burn injury, diabetic/vascular ulcer. The overall market is also presented from the perspective of different geographic regions and the key countries in each region. The market has been segmented into four regions: North America, Europe, Asia-pacific and Rest of the World. Major markets for tissue engineered skin substitute are analyzed for each region with market share analysis and regulations. 

These companies offer wide range of products along with services, tailored to the requirements of industry verticals thereby augmenting their respective positions in the market.

Sample Companies Profiled in this Report are:
  • 3M Inc (U.S.),
  • BSN Medical GmbH (Germany),
  • Convatec Group Plc (U.K.),
  • Molnlycke Healthcare AB (Sweden),
  • Organogenesis Inc. (U.S.),
  • 10+.
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports